Panbela Therapeutics Inc. (PBLA)

Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts

Panbela Therapeutics, Inc. (NASDAQ:PBLA – Free Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for Panbela Therapeutics in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.07) for the quarter, down from their prior estimate of ($1.28). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Panbela Therapeutics’ current full-year earnings is ($8.38) per share. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($2.07) EPS, Q4 2024 earnings at ($1.98) EPS, FY2024 earnings at ($8.38) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($1.01) EPS. Separately, Roth Mkm reissued a “buy” rating on shares of Panbela Therapeutics in a report on Wednesday, March 27th. Read Our Latest Research Report on Panbela Therapeutics Panbela Therapeutics Stock Performance Shares of PBLA stock opened at $0.44 on Monday. The stock’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $5.94. The firm has a market capitalization of $1.53 million, a PE ratio of 0.00 and a beta of 1.55. Panbela Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $243.06. Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($65.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($24.34) by ($41.56). About Panbela Therapeutics (Get Free Report) Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. Read More Five stocks we like better than Panbela Therapeutics What Are Growth Stocks and Investing in Them MarketBeat Week in Review – 5/13 – 5/17 What is Forex and How Does it Work? Take-Two Interactive Software Offers 2nd Chance for Investors Using the MarketBeat Dividend Tax Calculator Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook